News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.
|Title||Efficacy, safety, and immunology of an inactivated alum-adjuvant enterovirus 71 vaccine in children in China: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.|
|Publication Type||Journal Article|
|Year of Publication||2013|
|Authors||Zhu F-C, Meng F-Y, Li J-X, Li X-L, Mao Q-Y, Tao H, Zhang Y-T, Yao X, Chu K, Chen Q-H, Hu Y-M, Wu X, Liu P, Zhu L-Y, Gao F, Jin H, Chen Y-J, Dong Y-Y, Liang Y-C, Shi N-M, Ge H-M, Liu L, Chen S-G, Ai X, Zhang Z-Y, Ji Y-G, Luo F-J, Chen X-Q, Zhang Y, Zhu L-W, Liang Z-L, Shen X-L|
|Date Published||2013 Jun 8|
A vaccine for enterovirus 71 (EV71) is needed to address the high burden of disease associated with infection. We assessed the efficacy, safety, immunogenicity, antibody persistence, and immunological correlates of an inactivated alum-adjuvant EV71 vaccine.